Prostate MRI: The Clinician's View
Clare Tempany-Afdhal1
1MGB/Harvard, United States

Synopsis

This session will combine the expertise of a clinician and MR physicist using a SWOT approach to the challenges of MR imaging of Prostate cancer. Prostate MRI can avoid unnecessary biopsy using the PI-RADS assessment scores (all qualitative) suspicious lesions can be identified, scored, and targeted during biopsy. Current challenges include reliable quantitative metrics of cancer, uniformly high-quality exams. There are multiple new MR pulses sequences under investigation to enrich our current protocols. Several of these will lead to quantifiable metrics which can add further validation of mpMRI for detection, characterization and monitoring of men with suspected prostate cancer.

Clare Tempany- Syllabus for ISMRM 2022 Specialty area: SWOT (Strengths, Weaknesses, Opportunities & Threats) of Different Contrast Mechanisms Throughout the Brain & Body Talk: Prostate MRI: The Clinician’s View
Speaker name: Clare Tempany MD Brigham & Women’s Hospital Boston MA USA. ctempany@bwh.harvard.edu
Highlights:
Prostate cancer 2022
Normal anatomy of Prostate
Pathology of Cancer
MRI techniques for imaging the prostate gland
PI-RADS
What the patient and his doctors need- Current challenges
Target Audience: Researchers and clinicians who are interested in an introduction to Prostate cancer, role, use of PI-RADS and challenges for MRI
Outcome: Following this lecture, the audience will be familiar with the current clinical issues facing men before and after a diagnosis of Prostate cancer and the new and exciting role of MRI in addressing these issues. Purpose: There is now level 1 evidence supporting the role of Prostate MRI to avoid unnecessary biopsy in those with a negative MRI. Using the PI-RADS assessment scores (all qualitative) suspicious lesions can be identified, scored, and targeted during biopsy. Current challenges include need for reliable quantitative metrics of cancer, uniformly high-quality exams, Methods This lecture will focus initially on the current facts about Prostate cancer, a review of the normal anatomy, pathology of cancer and the MR techniques. It will also provide the attendees with a short review of the current globally accepted standards for MRI image interpretation and reporting using PI-RADS. Selected landmark clinical trials and results will be reviewed.

Acknowledgements

NIH Grant support P41 028741

References

References

1. Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, Margolis D, Schnall MD, Shtern F, Tempany CM, Thoeny HC, Verma S. PI-RADS Prostate Imaging - Reporting and Data System: Version 2.0 Eur Urol 2016 Jan;69(1):16-40. PMID: 26427566

2. Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, Tempany CM, Choyke PL, Cornud F, Margolis DJ, Thoeny HC, Verma S, Barentsz J, Weinreb JC. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. 2019 Sep;76(3):340-351. doi: 10.1016/j.eururo.2019.02.033. Epub 2019 Mar 18. PMID: 30898406.

3. Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, Kirkham AP, Oldroyd R, Parker C, Emberton M; PROMIS study group. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017 Feb 25;389(10071):815-822. doi: 10.1016/S0140-6736(16)32401-1. Epub 2017 Jan 20. PMID: 28110982.

4. Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budäus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM; PRECISION Study Group Collaborators. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018 May 10;378(19):1767-1777. doi: 10.1056/NEJMoa1801993. Epub 2018 Mar 18. PMID: 29552975.

5. Stabile A, Giganti F, Rosenkrantz AB, Taneja SS, Villeirs G, Gill IS, Allen C, Emberton M, Moore CM, Kasivisvanathan V. Multiparametric MRI for prostate cancer diagnosis: current status and future directions. Nat Rev Urol. 2020 Jan;17(1):41-61. doi: 10.1038/s41585-019-0212-4. Epub 2019 Jul 17. PMID: 31316185.

Proc. Intl. Soc. Mag. Reson. Med. 30 (2022)